DEXKETOPROFEN
Obesity, Adolescent
Qazvin University Of Medical SciencesSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Obesity, Adolescent cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Signe Torekov | Phase 4 | BB |
Alpha Tocopherol Indonesia University | Phase 4 | BB |
Liraglutide Medical University of Vienna | Phase 4 | BB |
MIDAZOLAM Asklepieion Voulas General Hospital | Phase 2 | CCC |
Oxytocin Massachusetts General Hospital | Phase 2 | CCC |
Qsymia University of Minnesota | Phase 2 | CCC |
METAMIZOLE Qazvin University Of Medical Sciences | N/A | D |
NEPENTHE Qazvin University Of Medical Sciences | N/A | D |
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →